ImmunoCellular Therapeutics Ltd  

(Public, NYSEMKT:IMUC)   Watch this stock  
Find more results for IMUC
0.535
+0.010 (1.90%)
Mar 26 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.51 - 0.54
52 week 0.51 - 1.45
Open 0.52
Vol / Avg. 808,646.00/1.14M
Mkt cap 47.38M
P/E     -
Div/yield     -
EPS -0.16
Shares 90.25M
Beta 1.09
Inst. own 5%
May 6, 2015
Q1 2015 ImmunoCellular Therapeutics Ltd Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 12, 2015
Q4 2014 ImmunoCellular Therapeutics Ltd Earnings Call - Webcast
Mar 10, 2015
ImmunoCellular Therapeutics Ltd at ROTH Conference
Mar 9, 2015
Q4 2014 ImmunoCellular Therapeutics Ltd Earnings Release
Jan 12, 2015
ImmunoCellular Therapeutics Ltd at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -33.75% -34.66%
Return on average equity -36.52% -37.69%
Employees 4 -
CDP Score - -

Address

23622 Calabasas Rd Ste 300
CALABASAS, CA 91302-1672
United States - Map
+1-818-2642300 (Phone)
+1-818-2245287 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an approach to treat cancer in which a patient�s own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies. The Company�s products include ICT-107, ICT-140, ICT-121, ICT-109 and DIAAD. ICT-107, the pipeline product, is a Phase II therapeutic dendritic cell (DC) vaccine for the treatment of glioblastoma multiforme (GBM), the common and lethal type of brain cancer. ICT-107 is designed to activate a patient�s immune system to target six different tumor-associated antigens. In February 2012, it acquired a world-wide license from the University of Pennsylvania and The John Hopkins University (JHU).

Officers and directors

John S. Yu M.D. Chairman of the Board, Chief Scientific Officer
Age: 50
Bio & Compensation  - Reuters
Andrew Gengos President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Anthony J. Gringeri Ph.D. Senior Vice President - Strategic Resources
Age: 60
Bio & Compensation  - Reuters
David E. Fractor Principal Accounting Officer, Vice President - Finance
Age: 54
Bio & Compensation  - Reuters
Rahul Singhvi Lead Independent Director
Age: 49
Bio & Compensation  - Reuters
Richard H. Chin M.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Gary S. Titus Independent Director
Age: 54
Bio & Compensation  - Reuters